Sector News

New Pfizer CEO’s top priorities? Think China and pipeline, not deals: analyst

December 18, 2018
Life sciences

Wondering how much incoming Pfizer CEO Albert Bourla is going to shake things up at the drugmaker? Not much, apparently. “Ian’s vision is my vision,” Bourla said of predecessor Ian Read at an analyst lunch where he sketched out his plans.

Investors should “expect a smooth transition,” Credit Suisse’s Vamil Divan wrote in an investor note after the gathering.

That sentiment may not surprise Pfizer-watchers, considering Bourla is already on Read’s executive leadership team. But the succession announcement this fall touched off a wave of speculation about whether Bourla shared Read’s current conception of Pfizer—as a company propelled by its own pipeline—or his penchant for megadeals, well-documented in recent years.

“We think Bourla could be more aggressive when it comes to large-scale M&A appetite given the company’s need to generate growth beyond 2020,” Barclays analyst Geoff Meacham wrote to clients earlier this year.

For now, though, Bourla thinks Pfizer has plenty of opportunities to succeed on its own. In Asia, for instance.

“The opportunity for Pfizer in China in particular was raised multiple times during the lunch given volumes that are growing ‘exponentially’ and with that market now Pfizer’s second largest behind the U.S.,” Divan wrote.

Bourla also touted a pair of key pipeline prospects that could move the needle in 2019: anti-inflammatory product tanezumab and tafamidis, a treatment for polyneuropathy. The company will be plowing more money into R&D to help get those drugs and others through the clinic, shifting spending away from SG&A as it prepares for Lyrica’s fall off the patent cliff.

But it’s those same prospects that could put a damper on dealmaking activity, Divan noted. After all, big deals are distracting.

Pfizer will “continue to analyze various business development opportunities as they arise, but feel they have a unique window of opportunity to properly launch some of their upcoming products and do not want to risk that with the additional operational disruption a large deal might cause,” he wrote.

By Carly Helfand

Source: Fierce Pharma

Related News

July 31, 2021

Lonza positions collagen as “key” to future of joint health market

Life sciences

NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.

July 31, 2021

Novo Holdings co-leads Hemab’s US$ 55M Series A to advance next generation therapeutics for bleeding and thrombosis disorders

Life sciences

The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.

July 31, 2021

BD acquires Tepha to drive new innovations in soft tissue repair and regeneration

Life sciences

BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.

Send this to a friend